| 1 | Contraceptive (Launch Year) | 215.2K (units) | 215.7K (units) | 0.23% |
| 2 | Antimigraine (DTC) | 24.9% (repeat) | 25.1% (repeat) | 0.80% |
| 3 | Post-Menopausal (DTC) 800# | 0.7% (targ. aud.) | 0.616% (targ. aud.) | -12.00% |
| 4 | Antihypertensive (Launch Year) | 3.05 (share) | 3.1 (share) | 1.64% |
| 5 | Antihypertensive (Restage) | 2.9 (share) | 2.9 (share) | 0.00% |
| 6 | Antifungal (Launch Year) | 7.7 (share) | 7.8 (share) | 1.30% |
| 7 | Antihypertensive (Competitor) | 8.0 (share) | 7.9 (share) | -1.25% |
| 8 | Antihypertensive (Budget Cut) | 2.43 (share) | 2.5 (share) | 2.88% |
| 9 | Cholesterol Reducer | | | |
| | (12th Month NRx Retail Share) | 33.3 (share) | 34.1 (share) | 2.40% |
| | (24th Month NRx Retail Share) | 43.4 (share) | 41.7 (share) | -3.92% |
| | (36th Month NRx Retail Share) | 48.7 (share) | 46.9 (share) | -3.70% |
| | (48th Month NRx Retail Share) | 50.7 (share) | 51.0 (share) | 0.59% |
| 10 | Contraceptive (New Detailing & Sampling Plan) | 4,455,832 | 4,373,399 | -1.85% |
| 11 | NSAID (New Detailing & Sampling Plan) | 2,535,623 | 2,581,266 | 1.80% |
| 12 | Osteoporotic (Launch Year) | $48.3M | $49.4M | 2.28% |
| 13 | Cholesterol Reducer (Average of 12 Monthly Forecasts) | 1.41 (share) | 1.37 (share) | -2.84% |
| 14 | NSAID (Launch Year) | 20.5 (share) | 21.3 (share) | 3.90% |
| 15 | Antibiotic (Increment) | 4.19 (share pts.) | 4.36 (share pts.) | 4.06% |
| 16 | Oncologic (Volumetric Increment) | – | – | 3.10% |
| 17 | Seasonal Allergy (Launch Year) | 1.72 (share) | 1.62 (share) | -5.81% |
| 18 | Asthma (DTU) | 20.1% (incremental) | 19.5% (incremental) | -2.99% |
| 19 | NSAID (New Category; TRx Share at 12th month) | 33.21 (share) | 33.06 (share) | -0.45% |
| 20 | Antihypertensive (NRx Share at 12th month) | 0.67 (share) | 0.70 (share) | 4.48% |
| 21 | Antihypertensive (New Indication; Launch Year) | $31.1M | $32.2M | 3.54% |
| 22 | Prostate (Launch Year) | $24.3M | $23.7M | -2.47% |
| 23 | Off-Label Usage for Bipolar Disorder | 31.30% | 30.80% | -1.60% |
| 24 | New Formulation for Anti-Anxiety (1st 18 months NRx’s) | 295.2K | 296.8K | 0.54% |
| 25 | Oncologic | 6.1 (incr. share pts.) | 5.9 (incr.Share pts.) | -3.28% |
| 26 | Psychotropic (DTC) | 0.973M (incremental) | 1.028M (incremental) | 5.65% |
| 27 | Gynecological Diagnostic Device | $4.1MM | $4.2MM | 2.44% |
| 28 | Neurological (Launch Year) | 4.04% (projected) | 4.17% | 3.22% |
| 29 | Dyslipidemic (Launch Year) | 2,353,187 TRx’s | 2,291,201 TRx’s | -2.63% |
| 30 | Antimigraine New Formulation | | | |
| | (Launch Year TRx Share) | 0.958 (Share) | 0.953 (Share) | -0.52% |
| | (Year 2 TRx Share) | 1.214 (Share) | 1.252 (Share) | 3.13% |
| 31 | Epilepsy | | | |
| | (12th Month TRx Share) | 1.151 (TRx Share) | 1.184 (TRx Share) | 2.87% |
| | (18th Month TRx Share) | 1.508 (TRx Share) | 1.501 (TRx Share) | -0.46% |
| 32 | New Rheumatology Biologic – including forecasting DTC | | | |
| | (12th Month) | 7.9 (% of Class Leader) | 7.8 (% of Class Leader) | -1.27% |
| | (18th Month) | 10.9 (% of Class Leader) | 11.2 (% of Class Leader) | 2.75% |
| 33 | Hospital Antibiotic – including forecasting Payer access | | | |
| | (12th Month) | 12,045 days of therapy | 12,462 days of therapy | 3.46% |
| 34 | Injectable Anti-Diabetic (12th Month) | 43,570 (patients) | 44,859 (patients) | 3.0% |
| 35 | Hyperlipidemia and Cardiovascular outcomes (New Indication Launch Year) | 36.4 (TRx share) | 37.5 (TRx share) | -2.9% |
| 36 | Parkinson’s Disease late-stage treatment (1-Year) | $99.2M | $102.1M | 2.9% |
| 37 | Vaccine (Launch Year) | 245,839 (doses) | 261,029 (doses) | 6.2% |
| 38 | Vaccine (Launch Year) | 3,343,780 (doses) | 3,479,014 (doses) | 4.0% |
| 39 | DTC Incremental Atypical Antipsychotic (15 Months) | 96,824 TRx’s | 94,874 TRx’s | -2.0% |
| Mean Absolute Percentage Error | 2.8% |
